Compare BBSI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | ERAS |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.4M | 1.0B |
| IPO Year | 1993 | 2021 |
| Metric | BBSI | ERAS |
|---|---|---|
| Price | $38.14 | $6.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $45.50 | $3.88 |
| AVG Volume (30 Days) | 161.5K | ★ 5.4M |
| Earning Date | 02-25-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 10.03 | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $1,223,992,000.00 | N/A |
| Revenue This Year | $10.70 | N/A |
| Revenue Next Year | $7.58 | N/A |
| P/E Ratio | $18.17 | ★ N/A |
| Revenue Growth | ★ 9.64 | N/A |
| 52 Week Low | $33.01 | $1.01 |
| 52 Week High | $49.65 | $6.49 |
| Indicator | BBSI | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 87.88 |
| Support Level | $36.73 | $3.36 |
| Resistance Level | $37.47 | $6.49 |
| Average True Range (ATR) | 0.81 | 0.62 |
| MACD | 0.23 | 0.28 |
| Stochastic Oscillator | 91.62 | 97.31 |
Barrett Business Services Inc is a provider of payroll administrative services and staffing services. The company categories of services include professional employer services and staffing. Professional employer services offer payroll management, payroll tax services, and workers' compensation coverage solutions, as well as workforce management services, including hiring and termination of employees. Staffing offers temporary staffing services, as well as contract staffing, long-term or indefinite on-site management, and direct placement services. The company operates in the United States of America. It generates maximum revenue from the Professional employer service fees.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.